RELMADA THERAPEUTICS, INC.

Analyst Reco. Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
3.68 ^USD	-1.08%		-3.92%	-11.11%

03-19	Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
03-19	Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating	23-01-23	MT
Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target	22-12-09	MT
Goldman Sachs Downgrades Relmada Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $81	22-10-14	MT
Guggenheim Downgrades Relmada Therapeutics to Neutral From Buy	22-10-14	MT
Truist Securities Downgrades Relmada Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $90	22-10-13	MT
Oppenheimer Downgrades Relmada Therapeutics to Perform From Outperform, Adjusts Price Target to $7 From $64	22-10-13	MT
Goldman Sachs Adjusts Price Target on Relmada Therapeutics to $81 From $49, Reiterates Buy Rating	22-09-23	MT
Guggenheim Adjusts Price Target on Relmada Therapeutics to $60 From $50, Reiterates Buy Rating	22-09-06	MT
Goldman Sachs Adjusts Price Target for Relmada Therapeutics to $49 From $47, Maintains Buy Rating	22-08-12	MT
Oppenheimer Adjusts Relmada Therapeutics' Price Target to $64 From $75, Maintains Outperform Rating	22-05-09	MT
Goldman Sachs Adjusts Relmada Therapeutics' Price Target to $53 from $69, Keeps Buy Rating	22-03-24	MT
SVB Leerink Adjusts Relmada Therapeutics' Price Target to $42 from $50, Keeps Outperform Rating	21-12-20	MT
Mizuho Securities Starts Relmada Therapeutics at Buy With $50 Price Target	21-11-18	MT
RELMADA THERAPEUTICS : Truist Securities Adjusts Relmada Therapeutics PT to $90 From $75, Maintains Buy Rating	21-07-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer